Anti-LOX-1 therapy in rats with diabetes and dyslipidemia: Ablation of renal vascular and epithelial manifestations

Jesus H. Dominguez, Jawahar L. Mehta, Dayuan Li, Pengfei Wu, Katherine J. Kelly, C. Subah Packer, Constance Temm, Erin Goss, Liang Cheng, Shaobo Zhang, Carolyn E. Patterson, John W. Hawes, Richard Peterson

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

LOX-1 is a multifunctional membrane receptor that binds and internalizes oxidized LDL (oxLDL). We tested the hypothesis that blockade of LOX-1 with an anti-LOX-1 antibody limits nephropathy in male rats with diabetes and dyslipidemia (ZS rats; F1 hybrid product of Zucker fatty diabetic rats and spontaneous hypertensive heart failure rats). Lean ZS rats were controls, while untreated obese ZS (OM), ZS obese rats injected with nonspecific rabbit IgG (OM-IgG; 2 μg intravenous injection given weekly), and obese ZS rats given anti-LOX-1 rabbit antibody (OM-Ab; 2 μg intravenous injection given weekly) were the experimental groups. The rats were treated from 6 to 21 wk of age. All obese groups had severe dyslipidemia and hyperglycemia. Kidneys of obese rats expressed LOX-1 in capillaries and tubules, were larger, accumulated lipid, had intense oxidative stress, leukocyte infiltration, depressed mitochondrial enzyme level and function, and peritubular fibrosis (all P < 0.05 vs. lean ZS rats). Injections with LOX-1 antibody limited these abnormalities (P < 0.01 vs. data in OM or OM-lgG rats). In vitro, renal epithelial LOX-1 expression was verified in a cultured proximal tubule cell line. Our study indicates that anti-LOX-1 (vascular and epithelial) therapy may effectively reverse critical pathogenic elements of nephropathy in diabetes and dyslipidemia.

Original languageEnglish (US)
Pages (from-to)F110-F119
JournalAmerican Journal of Physiology - Renal Physiology
Volume294
Issue number1
DOIs
StatePublished - Jan 1 2008

Fingerprint

Dyslipidemias
Blood Vessels
Kidney
Therapeutics
Intravenous Injections
Antibodies
Immunoglobulin G
Rabbits
Hyperglycemia
Oxidative Stress
Leukocytes
Fibrosis
Heart Failure
Lipids
Cell Line
Injections
Membranes

Keywords

  • Atherosclerosis
  • Diabetic nephropathies
  • Renal failure

ASJC Scopus subject areas

  • Physiology

Cite this

Anti-LOX-1 therapy in rats with diabetes and dyslipidemia : Ablation of renal vascular and epithelial manifestations. / Dominguez, Jesus H.; Mehta, Jawahar L.; Li, Dayuan; Wu, Pengfei; Kelly, Katherine J.; Packer, C. Subah; Temm, Constance; Goss, Erin; Cheng, Liang; Zhang, Shaobo; Patterson, Carolyn E.; Hawes, John W.; Peterson, Richard.

In: American Journal of Physiology - Renal Physiology, Vol. 294, No. 1, 01.01.2008, p. F110-F119.

Research output: Contribution to journalArticle

Dominguez, Jesus H. ; Mehta, Jawahar L. ; Li, Dayuan ; Wu, Pengfei ; Kelly, Katherine J. ; Packer, C. Subah ; Temm, Constance ; Goss, Erin ; Cheng, Liang ; Zhang, Shaobo ; Patterson, Carolyn E. ; Hawes, John W. ; Peterson, Richard. / Anti-LOX-1 therapy in rats with diabetes and dyslipidemia : Ablation of renal vascular and epithelial manifestations. In: American Journal of Physiology - Renal Physiology. 2008 ; Vol. 294, No. 1. pp. F110-F119.
@article{ad2510e1e3004b6a89932605152f3551,
title = "Anti-LOX-1 therapy in rats with diabetes and dyslipidemia: Ablation of renal vascular and epithelial manifestations",
abstract = "LOX-1 is a multifunctional membrane receptor that binds and internalizes oxidized LDL (oxLDL). We tested the hypothesis that blockade of LOX-1 with an anti-LOX-1 antibody limits nephropathy in male rats with diabetes and dyslipidemia (ZS rats; F1 hybrid product of Zucker fatty diabetic rats and spontaneous hypertensive heart failure rats). Lean ZS rats were controls, while untreated obese ZS (OM), ZS obese rats injected with nonspecific rabbit IgG (OM-IgG; 2 μg intravenous injection given weekly), and obese ZS rats given anti-LOX-1 rabbit antibody (OM-Ab; 2 μg intravenous injection given weekly) were the experimental groups. The rats were treated from 6 to 21 wk of age. All obese groups had severe dyslipidemia and hyperglycemia. Kidneys of obese rats expressed LOX-1 in capillaries and tubules, were larger, accumulated lipid, had intense oxidative stress, leukocyte infiltration, depressed mitochondrial enzyme level and function, and peritubular fibrosis (all P < 0.05 vs. lean ZS rats). Injections with LOX-1 antibody limited these abnormalities (P < 0.01 vs. data in OM or OM-lgG rats). In vitro, renal epithelial LOX-1 expression was verified in a cultured proximal tubule cell line. Our study indicates that anti-LOX-1 (vascular and epithelial) therapy may effectively reverse critical pathogenic elements of nephropathy in diabetes and dyslipidemia.",
keywords = "Atherosclerosis, Diabetic nephropathies, Renal failure",
author = "Dominguez, {Jesus H.} and Mehta, {Jawahar L.} and Dayuan Li and Pengfei Wu and Kelly, {Katherine J.} and Packer, {C. Subah} and Constance Temm and Erin Goss and Liang Cheng and Shaobo Zhang and Patterson, {Carolyn E.} and Hawes, {John W.} and Richard Peterson",
year = "2008",
month = "1",
day = "1",
doi = "10.1152/ajprenal.00013.2007",
language = "English (US)",
volume = "294",
pages = "F110--F119",
journal = "American Journal of Physiology - Renal Physiology",
issn = "0363-6127",
number = "1",

}

TY - JOUR

T1 - Anti-LOX-1 therapy in rats with diabetes and dyslipidemia

T2 - Ablation of renal vascular and epithelial manifestations

AU - Dominguez, Jesus H.

AU - Mehta, Jawahar L.

AU - Li, Dayuan

AU - Wu, Pengfei

AU - Kelly, Katherine J.

AU - Packer, C. Subah

AU - Temm, Constance

AU - Goss, Erin

AU - Cheng, Liang

AU - Zhang, Shaobo

AU - Patterson, Carolyn E.

AU - Hawes, John W.

AU - Peterson, Richard

PY - 2008/1/1

Y1 - 2008/1/1

N2 - LOX-1 is a multifunctional membrane receptor that binds and internalizes oxidized LDL (oxLDL). We tested the hypothesis that blockade of LOX-1 with an anti-LOX-1 antibody limits nephropathy in male rats with diabetes and dyslipidemia (ZS rats; F1 hybrid product of Zucker fatty diabetic rats and spontaneous hypertensive heart failure rats). Lean ZS rats were controls, while untreated obese ZS (OM), ZS obese rats injected with nonspecific rabbit IgG (OM-IgG; 2 μg intravenous injection given weekly), and obese ZS rats given anti-LOX-1 rabbit antibody (OM-Ab; 2 μg intravenous injection given weekly) were the experimental groups. The rats were treated from 6 to 21 wk of age. All obese groups had severe dyslipidemia and hyperglycemia. Kidneys of obese rats expressed LOX-1 in capillaries and tubules, were larger, accumulated lipid, had intense oxidative stress, leukocyte infiltration, depressed mitochondrial enzyme level and function, and peritubular fibrosis (all P < 0.05 vs. lean ZS rats). Injections with LOX-1 antibody limited these abnormalities (P < 0.01 vs. data in OM or OM-lgG rats). In vitro, renal epithelial LOX-1 expression was verified in a cultured proximal tubule cell line. Our study indicates that anti-LOX-1 (vascular and epithelial) therapy may effectively reverse critical pathogenic elements of nephropathy in diabetes and dyslipidemia.

AB - LOX-1 is a multifunctional membrane receptor that binds and internalizes oxidized LDL (oxLDL). We tested the hypothesis that blockade of LOX-1 with an anti-LOX-1 antibody limits nephropathy in male rats with diabetes and dyslipidemia (ZS rats; F1 hybrid product of Zucker fatty diabetic rats and spontaneous hypertensive heart failure rats). Lean ZS rats were controls, while untreated obese ZS (OM), ZS obese rats injected with nonspecific rabbit IgG (OM-IgG; 2 μg intravenous injection given weekly), and obese ZS rats given anti-LOX-1 rabbit antibody (OM-Ab; 2 μg intravenous injection given weekly) were the experimental groups. The rats were treated from 6 to 21 wk of age. All obese groups had severe dyslipidemia and hyperglycemia. Kidneys of obese rats expressed LOX-1 in capillaries and tubules, were larger, accumulated lipid, had intense oxidative stress, leukocyte infiltration, depressed mitochondrial enzyme level and function, and peritubular fibrosis (all P < 0.05 vs. lean ZS rats). Injections with LOX-1 antibody limited these abnormalities (P < 0.01 vs. data in OM or OM-lgG rats). In vitro, renal epithelial LOX-1 expression was verified in a cultured proximal tubule cell line. Our study indicates that anti-LOX-1 (vascular and epithelial) therapy may effectively reverse critical pathogenic elements of nephropathy in diabetes and dyslipidemia.

KW - Atherosclerosis

KW - Diabetic nephropathies

KW - Renal failure

UR - http://www.scopus.com/inward/record.url?scp=38349026839&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38349026839&partnerID=8YFLogxK

U2 - 10.1152/ajprenal.00013.2007

DO - 10.1152/ajprenal.00013.2007

M3 - Article

C2 - 17989113

AN - SCOPUS:38349026839

VL - 294

SP - F110-F119

JO - American Journal of Physiology - Renal Physiology

JF - American Journal of Physiology - Renal Physiology

SN - 0363-6127

IS - 1

ER -